NIH Director's Blog: Drug Discovery

NOVEMBER 5, 2020

Because SARS-CoV-2 is so highly infectious, basic researchers without access to specially designed biosafety facilities may be limited in their ability to study the virus. While the quantum dots may bind and enter human cells just like the virus, they can’t cause an infection. 2020 Sep 22;14(9):12234-12247.

Research Laboratories 85

Research Laboratories Laboratories Science Drugs 85

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. In particular, two COVID-19 pneumonia patients administered at Seoul National University Hospital became virus-free within 10 days by administering hzVSF-v13 twice or three times. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

DECEMBER 15, 2020

15, 2020 — The U.S. Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. © 2020 HealthDay. Posted: December 2020. Professional. USPSTF Recommends Hep B Screen for At-Risk Teens, Adults. TUESDAY, Dec.

Virus 52

Virus Therapies Trials Treatment 52

Drug Target Review

SEPTEMBER 25, 2024

4 Another related and well described non-oncogene resistance mechanism is the histological transformation of EGFR-mutated non-small cell lung cancer (NSCLC) to small-cell lung cancer upon treatment with an EGFR inhibitor. Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

NOVEMBER 16, 2020

17, 2020 11:00 UTC. has sponsored and funded a new FDA Oversight Trial that seeks to restore respiratory function in adults who have suffered lung damage from the COVID-19 virus. Many of these patients, who have been told to get their affairs in order, experience improved lung function and quality of life after treatment.

Trials 52

Trials FDA Treatment Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

3, 2020 09:00 UTC. MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. Data have been made available on the bioRxiv.org pre-print server.

Disease 52

Disease Virus Treatment Therapies 52

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 40

Trials Treatment Small Molecule Hospitals 40

The Pharma Data

DECEMBER 23, 2020

While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s While Organicell and Cytodyn wait to hear back on their clinical trials and PureTech awaits the results of its Phase II study, Chen stated that this treatment area is ripe with need. . “We

Clinical Trials 52

Clinical Trials FDA Trials Small Molecule 52

Broad Institute

MAY 30, 2023

She realized the importance of her role in keeping the worms healthy, so she could later study their gene expression and behavior in response to different drug treatments. I love working on medical samples that are provided by patients because it motivates me to find them an answer or even a potential treatment.

Research 89

Research Medical Schools Doctors Science 89

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 29, 2020

29, 2020– Alexion Pharmaceuticals, Inc. NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Non-GAAP diluted EPS for the third quarter of 2020 was $3.24 , a 16 percent increase versus the third quarter of 2019. ” Third Quarter 2020 Financial Highlights. in the prior year.

Clinical Trials 40

Clinical Trials Trials Production Licensing 40

Molecular Design

AUGUST 9, 2020

> I sometimes wonder what percentage of the pharmacopoeia will have been proposed for repurposing for the treatment of COVID19 by the end of 2020. There are three general approaches to directly tackle a virus such as SARS-CoV-2 with a small molecule drug (or chemical agent).

Drugs 52

Drugs Virus Small Molecule Treatment 52

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . Food and Drug Administration as part of its review of our Emergency Use Authorization submission, and we continue to focus on completing our ongoing trials evaluating REGN-COV2 for the treatment and prevention of COVID-19.” TARRYTOWN, N.Y. , Regeneron has shared these results with the U.S.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 9, 2020

10, 2020 04:32 UTC. The offering is expected to close on or about December 14, 2020, subject to satisfaction of customary closing conditions. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Forward-looking Statements.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Therapies Trials 40

Creative Biolabs

JUNE 2, 2020

The results of the study were published online on May 18, 2020 in Nature. “There are no approved tools or approved treatments that have been shown to fight the coronavirus that causes COVID-19. It can neutralize SARS-CoV-2 virus by binding to the S protein fragment near the attachment site of the host cell.

Virus 52

Virus Clinical Trials Research Treatment 52

The Pharma Data

OCTOBER 19, 2020

19, 2020 — The U.S. from the KOF Swiss Economic Institute at ETH Zurich, and colleagues compared pre-post FFCRA changes in newly reported COVID-19 cases in states where workers gained the right to take paid sick leave (treatment group) to states where workers already had access to paid sick leave (control group). Professional.

Virus 52

Virus Treatment Research 52

The Pharma Data

NOVEMBER 23, 2020

23, 2020 — Fresh takes on the efficacy of fish oil and vitamin D, new treatments for heart failure patients, the cardiovascular effects of COVID-19 , and structural racism as a driver of health disparity were just a few of the major developments that emerged from the American Heart Association Scientific Sessions 2020, held virtually from Nov.

Research 52

Research Virus Therapies Trials 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

OCTOBER 31, 2020

1, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) ( Taiwan : 4157) announced today that U.S. Food and Drug Administration (“FDA”) has approved the Investigation New Drug (IND) application for TG-1000, a novel treatment for influenza A and B. TAIPEI, Taiwan , Nov.

FDA Approval 52

FDA Approval FDA Clinical Development Virus 52

The Pharma Data

JANUARY 3, 2021

Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosis (GM1). chief medical officer of Passage Bio. About PBGM01.

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Taken together, these factors suggest that Annamycin could represent an important treatment to help address a significant unmet need in patients with STS lung metastases. . .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

SEPTEMBER 17, 2020

The illness of one of the participants in the Oxford-AstraZeneca COVID-19 vaccine trial may not have been caused by the treatment itself, according to newly revealed information. . It uses a weakened version of the common cold virus and the genetic material of COVID-19’s spike protein. . Photo by Retha Ferguson. Conor Kavanagh.

Vaccine 52

Vaccine Trials Virus Treatment 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. and around the world.

Clinical Trials 52

Clinical Trials Virus Trials Treatment 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

AUGUST 31, 2020

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

DECEMBER 30, 2020

30 December 2020 — AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. The data were also published in The Lancet on 8 December 2020.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

DECEMBER 21, 2020

Extension eliminates out-of-pocket costs for treatment, allowing impacted members to focus on health and recovery for as long as the public health emergency lasts. 22, 2020 /PRNewswire/ — With new cases surging throughout the U.S, 22, 2020 /PRNewswire/ — With new cases surging throughout the U.S, OAKLAND, Calif. ,

Virus 52

Virus Clinical Research Treatment Disease 52

The Pharma Data

MARCH 5, 2021

The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020. Hepcludex is an important new addition to the Gilead portfolio.

Science 52

Science Therapies Virus Disease 52

The Pharma Data

JUNE 26, 2021

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Preclinical results were shared previously at the 8 th annual mRNA Healthcare Conference in November 2020.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 21, 2020

21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. Kimberly Smith, M.D., Kimberly Smith, M.D.,

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. 2020 Oct 15:eabe9403. Credit: DE Gordon et al.,

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

DECEMBER 4, 2020

4, 2020 — For kids with asthma , more time spent at home and donning masks due to the COVID-19 pandemic may be providing a reprieve from emergency symptoms, new research shows. 5 to May 23 in three separate years: 2018, 2019 and 2020. FRIDAY, Dec. In the new study, published online Dec. For the study, researchers separated Jan.

Hospitals 52

Hospitals Doctors Virus Treatment 52

The Pharma Data

NOVEMBER 23, 2020

23 November 2020 . Trial participants to date are aged 18 years or over, who are healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus. Posted: November 2020. Two different dosing regimens demonstrated efficacy with one showing a better profile.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52